I like to think I treat everyone fairly. And I’m not someone who holds a grudge.
But as I was reminded this morning, I have a life-long enemy.
No matter what I do, I just can’t seem to make things right between us.
So today, I’d like to tell you more about this situation.
It would be good to get it off my chest…
And as you’ll learn, it could also help you make at least 10x your money.
Meet My Life-Long Enemy
My enemy will be familiar to you. In fact, you have the same enemy yourself:
You see, aging is the single biggest factor for late-life chronic disease. It’s not just a risk factor — it’s the cause itself for diseases including Alzheimer’s, Parkinson’s, and cancer.
There are no cures for these diseases, and they’re responsible for $3 trillion in global healthcare costs annually.
But perhaps surprisingly, aging isn’t inevitable…
Thirty years of research has proven that aging isn’t predestined.
To the contrary, it’s controllable, manageable, malleable.
Furthermore, it’s druggable — meaning it can be treated with pharmaceutical agents, just like other biological conditions.
And now, simply by targeting age itself, scientists are aiming to increase the human lifespan.
And one company in particular is on the cutting-edge of this emerging field.
Introducing: Gerostate Alpha
Gerostate Alpha is a pharmaceutical startup.
Dedicated to treating aging and age-related disease, its mission is to extend lifespan itself, well beyond what was once thought possible.
Simply put, it aims to develop pharmaceuticals that can reduce the effects of aging.
For example, as you can see in the chart below, by targeting drugs aimed at the cardiovascular system, it could reduce the effects of aging stemming from heart failure. And by targeting drugs aimed at the pulmonary system, it could reduce the effects of aging that come from COPD.
Gerostate’s Progress and Next Steps
Gerostate has already screened 61,000 compounds that might help it achieve its goals.
30 of these compounds were found to extend lifespan in simple animal models, and 5 of these 30 were subsequently tested in mice.
Of the 5 compounds that were tested on mice, 1 resulted in measurable slowing of bone aging. Bone is a “major aging tissue” that’s representative of aging in general, so this is a big deal.
Now the company needs to test this compound’s effect on aging itself. For example, in addition to testing its effect on bone and muscle loss, it will see if it increases cognitive and cardiovascular functions.
It also plans to test 10 to 15 other compounds.
And since it will need FDA approval to commercialize any of its candidates, it will eventually need to evaluate each compound’s efficacy and safety, and complete clinical testing.
The thing is, if any of its candidates can get FDA approval (and granted, that’s a big “if”), this tiny startup could be the next blockbuster pharma company.
This is the type of early-stage venture that could potentially return at least 10x an investor’s capital — that’s our minimum target for any startup investment.
Furthermore, it’s currently raising capital from investors like you. The minimum is $100, and the valuation is $15 million.
Should you invest? Let’s take a look.
Investment Pros and Cons
On the “pro” side…
First of all, its team is strong. The Executive Chairman is the founder of Sangamo Therapeutics (Nasdaq: SGMO), a ~$2 billion pharma company. Furthermore, its team of three PhDs has been at the forefront of aging research for decades, collectively authoring 200+ papers.
Secondly, this team has already attracted the attention and capital of The National Institutes of Health, the primary agency of the U.S. government responsible for public health research. In fact, the NIH and other sponsors have previously granted the team $80 million.
And lastly, this team has attracted the attention of professional investors including YCombinator (whose alumni include billion-dollar homeruns like Airbnb and Dropbox), and CRCM Ventures, whose startup investments have already led to 6 IPOs and 18 acquisitions.
On the “con” side, the business of developing drugs is daunting. The estimated cost of getting a new drug to market can reach $1 billion. Furthermore, Gerostate is still early in its journey — it doesn’t expect its candidates to enter clinical studies for at least 18 months.
A Great Place to Start Your Search
But if you’re excited about destroying our mutual enemy — aging! — Gerostate is an exciting place to start your search.
Just remember: this is an early-stage venture, so you need to do substantial research before making an investment decision.
To learn more, just click here »
Please note: Crowdability has no relationship with any of the startups we write about. We’re an independent provider of education and research on startups and alternative investments.